ArticleJournal of molecular histology2025
Estragole protects against ovalbumin-induced allergic asthma by amelioration of interleukin-4 and interleukin-5 expression in BALB/c mice.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic respiratory disease characterized by airway hyper-responsiveness, inflammation, and pulmonary edema. Asthma may be triggered by allergens, certain medications, environmental exposure, respiratory infection, and physical exertion. Patients with asthma express higher levels of T helper cell 2 (Th2) cytokines i.e., IL-4 and IL-5. Estragole (EST), a phytochemical in essential oils, has shown anti-inflammatory and immunomodulatory effects. Current study was set out with the objectives to evaluate the anti-asthmatic effects of EST using various in vivo and in vitro experiments. Thirty-six (36) albino BALB/c mice were divided into six groups: Normal group (NG), OVA-induced asthma group (DG), Methylprednisolone group (MPG group, 15 mg/kg), Low, medium and high doses of EST (LDE: 10, 30 and 60 mg/kg, respectively). Mice were sensitized with 20 µg of OVA intraperitoneally and treated with EST during the challenge phase (21-27 days). Lung wet/dry ratio, total and differential leukocyte counts (TLC and DLC) in blood and Bronchoalveolar Lavage fluid (BALF) collections, histopathology (H&E, PAS), mRNA expressions of IL-4 and IL-5 in the lungs were analyzed, and molecular docking was performed. Airway inflammation was found ameliorated in EST treated groups as evident by reduction in TLC and DLC in both blood and BALF samples, and attenuation of infiltration of inflammatory cells in lungs. Furthermore, EST significantly reduced IL-4 and IL-5 mRNA expression levels in the lungs tissue and demonstrated notable binding affinity with IL-4 (- 4.5 kcal/mol), IL-5 (- 4.7 kcal/mol), and GATA-3 (- 5.3 kcal/mol). These docking results support the in vivo findings by suggesting a possible interaction of EST with key Th2 mediators, and their transcriptional regulator to suppress downstream airway inflammation, consistent with its observed anti-asthmatic effects. Estragole possesses anti-asthmatic property by attenuation of airway inflammation and pulmonary edema. Molecular docking, RT-qPCR, and histopathological evaluations suggesting that EST may attenuate allergic asthma via attenuation in Th2-mediated markers i.e., IL-4, IL-5, and GATA-3.
Indexed as
Identifiers
41186775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.